184 related articles for article (PubMed ID: 20548339)
1. Order of application and liver toxicity in patients given BU and CY containing conditioning regimens for allogeneic hematopoietic SCT.
Cantoni N; Gerull S; Heim D; Halter J; Bucher C; Buser A; Tsakiris DA; Passweg J; Tichelli A; Stern M; Gratwohl A
Bone Marrow Transplant; 2011 Mar; 46(3):344-9. PubMed ID: 20548339
[TBL] [Abstract][Full Text] [Related]
2. A Phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regimen.
Satwani P; Bhatia M; Garvin JH; George D; Dela Cruz F; Le Gall J; Jin Z; Schwartz J; Duffy D; van de Ven C; Foley S; Hawks R; Morris E; Baxter-Lowe LA; Cairo MS
Biol Blood Marrow Transplant; 2012 Feb; 18(2):324-9. PubMed ID: 22079471
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation.
Nagler A; Rocha V; Labopin M; Unal A; Ben Othman T; Campos A; Volin L; Poire X; Aljurf M; Masszi T; Socie G; Sengelov H; Michallet M; Passweg J; Veelken H; Yakoub-Agha I; Shimoni A; Mohty M
J Clin Oncol; 2013 Oct; 31(28):3549-56. PubMed ID: 23980086
[TBL] [Abstract][Full Text] [Related]
4. The effect of administration order of BU and CY on toxicity in hematopoietic SCT in humans.
Kerbauy FR; Tirapelli B; Akabane H; Oliveira JS
Bone Marrow Transplant; 2009 Jun; 43(11):883-5. PubMed ID: 19079309
[No Abstract] [Full Text] [Related]
5. [Efficacy and toxicity of intravenous busulfan-based conditioning before allogeneic peripheral blood stem cell transplantation for leukemia].
Tong XZ; Xu DR; Zou WY; Li J; Luo SK; Peng AH; Zhang GC; Zheng D
Ai Zheng; 2007 Aug; 26(8):914-8. PubMed ID: 17697559
[TBL] [Abstract][Full Text] [Related]
6. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience.
Ulrickson M; Aldridge J; Kim HT; Hochberg EP; Hammerman P; Dube C; Attar E; Ballen KK; Dey BR; McAfee SL; Spitzer TR; Chen YB
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1447-54. PubMed ID: 19822305
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Cyclophosphamide Combined with Total Body Irradiation, Oral Busulfan, or Intravenous Busulfan for Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Lymphoblastic Leukemia.
Mitsuhashi K; Kako S; Shigematsu A; Atsuta Y; Doki N; Fukuda T; Kanamori H; Onizuka M; Takahashi S; Ozawa Y; Kurokawa M; Inoue Y; Nagamura-Inoue T; Morishima Y; Mizuta S; Tanaka J;
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2194-2200. PubMed ID: 27638362
[TBL] [Abstract][Full Text] [Related]
8. Comparison of new flu-bu12-tg conditioning with the standard bu-cy myeloablative regimen in patients undergoing allogeneic stem cell transplantation for acute myeloid leukemia.
Raida L; Tucek P; Faber E; Vondrakova J; Rusinakova Z; Skoumalova I; Hubacek J; Jarosova M; Katrincsakova B; Pikalova Z; Kurfurst P; Indrak K
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Dec; 155(4):327-32. PubMed ID: 22336644
[TBL] [Abstract][Full Text] [Related]
9. Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial.
Seydoux C; Medinger M; Gerull S; Halter J; Heim D; Chalandon Y; Levrat SM; Schanz U; Nair G; Ansari M; Simon P; Passweg JR; Cantoni N
Ann Hematol; 2021 Jan; 100(1):209-216. PubMed ID: 33098041
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of two conditioning regimens in treatment of leukemia by allogeneic hematopoietic stem cell transplantation].
Zhang GC; Zheng D; Guan XX; Luo SK; Li J; Peng AH; Tong XZ; Lai FZ; Tan EX; Hong WD
Ai Zheng; 2003 Jun; 22(6):620-3. PubMed ID: 12948413
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the effects of preconditioning regimens on hepatic veno-occlusive disease in mice after hematopoietic stem cell transplantation.
Qiao J; Fu J; Fang T; Huang Y; Mi H; Yang N; Chen C; Xu K; Zeng L
Exp Mol Pathol; 2015 Feb; 98(1):73-8. PubMed ID: 25533545
[TBL] [Abstract][Full Text] [Related]
12. Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality.
McCune JS; Batchelder A; Deeg HJ; Gooley T; Cole S; Phillips B; Schoch HG; McDonald GB
Biol Blood Marrow Transplant; 2007 Jul; 13(7):853-62. PubMed ID: 17580264
[TBL] [Abstract][Full Text] [Related]
13. [Clinical outcome of allogeneic hematopoietic stem cell transplantation with FLAG sequential busulfan/cyclophosphamide conditioning regimen for refractory/relapsed acute myeloid leukemia].
Liu W; Li Y; Qiu ZX; Yin Y; Sun YH; Xu WL; Wang Q; Liang ZY; Dong YJ; Wang LH; Cen QN; Wang MJ; Wang WS; Ou JP; Ren HY
Zhonghua Nei Ke Za Zhi; 2018 Aug; 57(8):576-581. PubMed ID: 30060329
[No Abstract] [Full Text] [Related]
14. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients.
Kröger N; Zabelina T; Krüger W; Renges H; Stute N; Kabisch H; Jaburg N; Löliger C; Krüll A; Zander AR
Bone Marrow Transplant; 2001 Feb; 27(4):349-54. PubMed ID: 11313663
[TBL] [Abstract][Full Text] [Related]
15. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality.
Kashyap A; Wingard J; Cagnoni P; Roy J; Tarantolo S; Hu W; Blume K; Niland J; Palmer JM; Vaughan W; Fernandez H; Champlin R; Forman S; Andersson BS
Biol Blood Marrow Transplant; 2002; 8(9):493-500. PubMed ID: 12374454
[TBL] [Abstract][Full Text] [Related]
16. Intravenous busulfan-cyclophosphamide as a preparative regimen before allogeneic hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia.
Tang W; Wang L; Zhao WL; Chen YB; Shen ZX; Hu J
Biol Blood Marrow Transplant; 2011 Oct; 17(10):1555-61. PubMed ID: 21549217
[TBL] [Abstract][Full Text] [Related]
17. The effect of administration order of BU and CY on engraftment and toxicity in HSCT mouse model.
Sadeghi B; Jansson M; Hassan Z; Mints M; Hägglund H; Abedi-Valugerdi M; Hassan M
Bone Marrow Transplant; 2008 May; 41(10):895-904. PubMed ID: 18223695
[TBL] [Abstract][Full Text] [Related]
18. [A comparison of toxicity and efficacy between busulfan plus fludarabine and busulfan plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia].
Liu H; Fan ZP; Jiang QL; Huang F; Zhou HS; Zhang X; Yu GP; Wu MQ; Sun J; Liu QF
Zhonghua Nei Ke Za Zhi; 2012 Nov; 51(11):880-4. PubMed ID: 23291027
[TBL] [Abstract][Full Text] [Related]
19. Mortality outcomes after busulfan-containing conditioning treatment and haemopoietic cell transplantation in patients with Gilbert's syndrome: a retrospective cohort study.
McDonald GB; Evans AT; McCune JS; Schoch G; Ostrow JD; Gooley TA
Lancet Haematol; 2016 Nov; 3(11):e516-e525. PubMed ID: 27968820
[TBL] [Abstract][Full Text] [Related]
20. [Effect of BU and CY versus TBI and CY as conditioning regimens on the efficacy of haploidentical stem cell transplantation in patients with hematologic malignancy].
Shao Q; Han D; Liu D; Zheng X; Dong L; Wang Z; Ding L; Yan H; Wang H; Duan L
Zhonghua Xue Ye Xue Za Zhi; 2014 Jun; 35(6):505-10. PubMed ID: 24985173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
